DLX:NYSEDeluxe Corporation Analysis
Data as of 2026-03-29 - not real-time
$26.99
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Deluxe trades at $26.99, just below its 20‑day SMA (27.26) but above the 50‑day SMA (26.69) and well above the 200‑day SMA (20.97), indicating a short‑term pullback within a longer‑term bullish framework. The RSI sits at 49.9, essentially neutral, while the MACD histogram is slightly negative and the signal line is flagged “bearish,” suggesting modest downside pressure in the next few days. Volume is increasing, and the technical support at $25.65 provides a cushion before the next resistance at $28.31. The stock’s beta (~0.94) points to lower market‑risk volatility, yet the 30‑day volatility of ~29.5% is relatively high, reflecting price swings.
From a valuation standpoint, DLX appears undervalued – its trailing PE of 15 is well below the industry average of 28, and the DCF‑derived fair value of $29.67 implies roughly a 21% upside. The forward PE of 6.3 signals strong earnings growth expectations, while a 4.45% dividend yield and a 66% payout ratio are backed by positive free cash flow ($188 M) that comfortably exceeds the annual dividend outlay. However, the balance sheet is levered, with a debt‑to‑equity ratio over 220 and total debt of $1.5 B versus cash of $37 M, raising concerns about financial flexibility. Overall, the combination of attractive yield, solid cash generation, and a sizable valuation gap supports a buy stance for investors comfortable with moderate leverage risk.
From a valuation standpoint, DLX appears undervalued – its trailing PE of 15 is well below the industry average of 28, and the DCF‑derived fair value of $29.67 implies roughly a 21% upside. The forward PE of 6.3 signals strong earnings growth expectations, while a 4.45% dividend yield and a 66% payout ratio are backed by positive free cash flow ($188 M) that comfortably exceeds the annual dividend outlay. However, the balance sheet is levered, with a debt‑to‑equity ratio over 220 and total debt of $1.5 B versus cash of $37 M, raising concerns about financial flexibility. Overall, the combination of attractive yield, solid cash generation, and a sizable valuation gap supports a buy stance for investors comfortable with moderate leverage risk.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- price near technical support at $25.65
- neutral RSI and modest bearish MACD signal
- high dividend yield of 4.45%
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF upside of ~21% to $29.67
- forward PE of 6.3 indicating earnings acceleration
- stable free cash flow covering dividend
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- elevated debt‑to‑equity ratio over 220
- consistent dividend income
- long‑term cash flow generation
Key Metrics & Analysis
Financial Health
Revenue Growth2.80%
Profit Margin3.85%
P/E Ratio15.0
ROE12.63%
ROA5.69%
Debt/Equity221.65
P/B Ratio1.8
Op. Cash Flow$270.6M
Free Cash Flow$188.4M
Industry P/E28.1
Technical Analysis
TrendBullish
RSI49.9
Support$25.65
Resistance$28.31
MA 20$27.26
MA 50$26.69
MA 200$20.97
MACDBearish
VolumeIncreasing
Fear & Greed Index65.98
Valuation
Fair Value$29.67
Target Price$32.67
Upside/Downside21.03%
GradeUndervalued
TypeBlend
Dividend Yield4.45%
Risk Assessment
Beta0.94
Volatility29.53%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.